Galena Biopharma (GALE)
Galena Biopharma Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these GALE related companies
GALE News
RT @newkidontheblock $AMRN 17 before we go to FDA? - no and go back to the $GALE board
about 7 hours ago by studatnu
about 7 hours ago by studatnu
RT @Moore1022 anyone see $2 after ASCO meetings? $GALE < id luv to say yes but impo, im afraid it will be 2.50. sorry
about 23 hours ago by Bleedblue
about 23 hours ago by Bleedblue
$GALE there is no upcoming FDA meeting. It has been reiterated a number of times now. Only the ASCO Conference at very beginning of June.
about 2 days ago by jemberlin
about 2 days ago by jemberlin
@sgdombrosky $GALE Can you post the link to their calendar? I can't seem to find it on the FDA site.....
about 2 days ago by PattyA_F
about 2 days ago by PattyA_F
@SomeGuy900 $GALE Not aware of a meeting with the FDA!! Only the presentation ASCO June 1st through 5th. But don't know of meeting with FDA
about 4 days ago by BiopharmaPro
about 4 days ago by BiopharmaPro
@BiopharmaPro Isn't there a June 5 meeting with FDA for $GALE too?
about 4 days ago by SomeGuy900
about 4 days ago by SomeGuy900
@studatnu @MisterDevin $GALE is a patience little gem but I thnk after ASCO presenation of Phase II Neuvax you should start to see momentum
about 4 days ago by BiopharmaPro
about 4 days ago by BiopharmaPro
RT @MisterDevin: Will $GALE move right before #ASCO12 ???? I'm sick of the red, sick of it !! - get used to it, ur in $gale
about 4 days ago by studatnu
about 4 days ago by studatnu
RT @SomeGuy900 RT @talleyville0311 $GALE where is the brian nichols article on seeking alpha?
about 4 days ago by mydanilo
about 4 days ago by mydanilo
Galena Biopharma (GALE) Withdraws S-3 Registration; Shares Moving Higher
May 23, 11:45AM Street Insider
May 23, 11:45AM Street Insider
Unusual 11 Mid-Day Movers 05/17: (MEG) (GALE) (XG) Higher; (WFR) (SVNT) (DANG) Lower
May 17, 1:06PM Street Insider
May 17, 1:06PM Street Insider
Morning Movers 05/17: (MEG) (GALE) (VELT) Higher; (WFR) (AAP) (DANG) (VNET) Lower
May 17, 11:20AM Street Insider
May 17, 11:20AM Street Insider
RXi Pharmaceuticals’ Common Stock to Commence Trading under the Symbol “RXII”
May 10, 6:50AM Business Wire
May 10, 6:50AM Business Wire
RXi Pharmaceuticals Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer
May 10, 6:50AM Business Wire
May 10, 6:50AM Business Wire
Galena Biopharma (GALE) Gets U.S. Patent Allowance for FBP Peptide Variants
May 01, 7:06AM Street Insider
May 01, 7:06AM Street Insider
Galena Biopharma Takes Final Actions to Complete Spin-Off of RXi Pharmaceuticals
Apr 26, 7:09AM Benzinga
Apr 26, 7:09AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GALE | 1.28 | -0.03 | -2.29% | 62.25M |
| GAIN | 7.30 | +0.14 | +1.96% | 158.09M |
| GAIA | 3.98 | +0.05 | +1.27% | 89.21M |
| GAI | 6.19 | +0.54 | +9.56% | 19.99M |
| GAGA | 4.95 | -0.07 | -1.39% | 230.27M |
| GAF | 65.06 | +0.38 | +0.58% | |
| GABC | 18.43 | +0.12 | +0.66% | 230.71M |
| FFIN | 32.56 | +0.23 | +0.71% | 1.017B |
| FFIC | 13.03 | -0.04 | -0.31% | 405.17M |
| FFI | 0.1701 | +0.00 | +0.00% | 2.090M |
